News And Updates

AstraZeneca’s Farxiga® Letters: What Pharmacies Need to Know Right Now

AstraZeneca's new Farxiga letters demand detailed pharmacy data, signaling stricter oversight. How pharmacies can respond safely and limit PBM exposure.

Return to Top

If your pharmacy dispenses Farxiga® (dapagliflozin), you may have received a second formal letter from AstraZeneca. These new communications, sent out in mid-September, aren’t routine follow-ups. They represent a clear escalation in how the manufacturer is scrutinizing pharmacies’ dispensing and purchasing data. In this new round of demands, AstraZeneca claims that the number of Farxiga® tablets dispensed exceeds those purchased through authorized channels. Pharmacies are requested to provide detailed summaries of 2024–2025 purchases, dispensing data broken down by payor and month, and proof of communication with PBMs about any “impacted” claims. This is part of a broader trend—manufacturers are increasingly using data to “police” distribution chains. What starts as a “verification” can easily snowball into enforcement. Similar demands can be expected from other manufacturers targeting high-cost and specialty products in the near future.

The tone and scope of the AstraZeneca Farxiga letters suggest serious implications for pharmacy providers. The potential of PBM exposure and compliance risks should not be disregarded and pharmacy operators should engage qualified, experienced counsel to guide them in considering a strategically sound, limited and appropriate response avoiding admissions against interest, speculation or regulatory non-compliance.

At MDRXLAW, we’ve guided pharmacies through manufacturer and PBM investigations for over 15 years. If you’ve received a Farxiga® demand or reconciliation letter, contact our experience healthcare attorneys as MDRXLaw by emailing info@mdrxlaw.com or calling our office at 212.668-0222.

Attorney Advertising. Prior results do not guarantee a similar outcome. This website is for general information only and is not legal advice. Viewing it or contacting the firm does not create an attorney-client relationship, and you should not send confidential information until the firm has confirmed it represents you.

Privacy Policy · Opt out of targeted ads